A2780

A2780

Cat.No.: CSC-C9491J

Species: Homo sapiens (Human)

Source: Ovary

Morphology: Epithelial

Culture Properties: Adherent

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C9491J
Description
The A2780 human ovarian cancer cell line was established from tumour tissue from an untreated patient. Cells grow as a monolayer and in suspension in spinner cultures. A2780 is the parent line to the cisplatin resistant cell line A2780 cis and the adriamycin resistant cell line A2780 ADR.
Species
Homo sapiens (Human)
Source
Ovary
Recommended Medium
RPMI 1640 + 2mM Glutamine + 10% Fetal Bovine Serum (FBS)
Culture Properties
Adherent
Morphology
Epithelial
Disease
Ovarian Endometrioid Adenocarcinoma
Storage
Creative Bioarray ships frozen cells on dry ice. On receipt, immediately transfer frozen cells to liquid nitrogen (-180 °C) until ready for experimental use.
Never can cryopreserved cells be kept at -20 °C.
Synonyms
A-2780; 2780; A2780S; A2780par
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

A2780 is a human ovarian endometrioid adenocarcinoma cell line, originally established in 1972 from an untreated patient with advanced-stage disease. Its singular scientific advantage resides in its status as the chemotherapy-sensitive parental archetype for isogenic drug resistance research. Unlike heterogeneous patient samples, A2780 provides a pure, syngeneic background against which resistance mechanisms can be experimentally isolated.

The line's power lies in its derivative platform. Chronic exposure of A2780 to cisplatin and adriamycin has generated the widely adopted resistant sublines A2780cis and A2780ADR, which exhibit cross-resistance to melphalan, vinblastine, and irradiation. This matched pair enables precise dissection of ATP-binding cassette (ABC) transporter efflux (MDR1/BCRP), EMT programming (VIM, SNAIL1/2), and ECM-mediated chemoprotection-mechanisms often confounded in non-isogenic comparisons.

Genomically, A2780 harbors clinically relevant driver mutations in TP53, BRCA1, PTEN (homozygous deletion), PIK3CA, and ATM. It retains stable, authenticated STR profiles and forms tumors in nude mice, bridging monolayer screening and in vivo efficacy. Critically, A2780 is exquisitely amenable to 3D multicellular spheroid culture, a configuration that recapitulates solid tumor hypoxia, G0-G1 cell cycle arrest, and p27-mediated chemoresistance-features lost in 2D.

NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines

Cells | DOI | Paper |

Background

This study compares NMR metabolomics profiles of A2780 ovarian cancer cells, cisplatin-resistant A2780cis, and primary high-grade serous ovarian cancer cells from 10 patients. Primary cells from solid tumors and ascites are metabolically similar to each other but differ significantly from A2780 and A2780cis. Exo-metabolome of patient-derived cells is closer to resistant A2780cis, while endo-metabolome is intermediate. Primary cells show pronounced glycolytic phenotype; A2780cis diverges via resistance markers like glutathione and taurine. Findings highlight limitations of A2780 as a representative HGSOC model and support A2780cis for resistance studies.

Key Findings

NMR metabolomics revealed that primary high-grade serous ovarian cancer (HGSOC) cells, whether derived from solid tumors (HGSOC_T) or ascites (HGSOC_A), share highly similar metabolic profiles across patients, but differ markedly from A2780 and cisplatin-resistant A2780cis cell lines. In the exo-metabolome, HGSOC_T cells cluster near A2780cis, while HGSOC_A cells separate; in the endo-metabolome, HGSOC cells are intermediate between A2780 and A2780cis. Primary cells display the most pronounced glycolytic phenotype, with increased glucose consumption, pyruvate uptake, and intracellular lactate. A2780cis cells are distinguished by elevated phosphocholine, glycerophosphocholine, glutathione, taurine, and altered urea cycle metabolites, indicating acquired cisplatin resistance mechanisms. HGSOC cells lack these resistance markers despite having higher cisplatin IC50 values than A2780. Additionally, UDP-sugar and nucleotide profiles differ: UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine are detectable only in immortalized lines, whereas UDP-glucose and inosine are specific to primary HGSOC cells. The study demonstrates that A2780 is not a faithful metabolic model of HGSOC, whereas A2780cis better mirrors some exo-metabolic features of primary cells.

Contribution

Creative Bioarray supplied the A2780 human ovarian carcinoma cell line and its cisplatin-resistant counterpart A2780cis (catalogue nos. CSC-C9491J and CSC-C9492J) used as established in vitro models. These cells enabled comparative NMR metabolomics against patient-derived HGSOC cells, serving as sensitive and resistant references throughout the study.

Box plots showing the relative concentration of intracellular metabolites that result significantly altered in the different cell lines.
Fig. 1. Box plots showing the relative concentration of intracellular metabolites that result significantly altered in the different cell lines.

Fluorescent NHC Gold(I) Complexes as Tools for Target Identification and Metallomic Studies in Cancer Cells

Inorganic Chemistry | DOI | Paper |

Background

This study reports three fluorescent NHC gold(I) complexes designed as trackable metallodrug models. Two anthracenyl-labeled complexes (3, 4) and one BODIPY-labeled complex (5) were synthesized and characterized. Their interactions with human serum albumin were examined by UV–vis and ESI-MS, revealing compound-dependent binding. Cellular uptake was monitored by FACS in cisplatin-sensitive and resistant A2780 ovarian cancer cells, and subcellular distribution was quantified by fractionation. The anthracenyl complexes retained cytotoxicity, with biscarbene 4 being most active and preferentially accumulating in mitochondria, supporting fluorescent tagging for mechanistic and metallomic studies.

Key Findings

Three NHC gold(I) complexes bearing anthracenyl (3, 4) or BODIPY (5) fluorescent tags were prepared. Anthracenyl monocarbene 3 and biscarbene 4 remained cytotoxic in A2780 cells; cationic biscarbene 4 was more potent than 3 and, notably, both were more active against cisplatin-resistant A2780/R than sensitive A2780/S cells. Complex 5 was too insoluble for reliable IC50 determination and showed unsuitable broad fluorescence. HSA studies showed that 3 forms covalent Au-NHC adducts, 4 interacts weakly/noncovalently, and 5 undergoes ligand displacement with gold(I) binding to HSA. FACS revealed efficient uptake of 3 and 4, with higher signal for 4. Subcellular fractionation showed preferential mitochondrial accumulation of both anthracenyl complexes. These results provide proof-of-concept that fluorescently labeled gold(I) NHC complexes can track uptake, subcellular fate, and protein interactions for metallomic target identification.

Contribution

Creative Bioarray supplied the A2780 human ovarian cancer cell lines used in this study, including cisplatin-sensitive (Lot CSC-C9491J) and cisplatin-resistant (Lot CSC-C9492J) variants. These authenticated cells enabled the MTT cytotoxicity assays, flow-cytometry uptake measurements, and subcellular fractionation experiments, supporting evaluation of the fluorescent gold(I) NHC complexes.

Cellular distribution of complexes 3 and 4 within the cytosol and mitochondria.
Fig. 2. Cellular distribution of complexes 3 and 4 within the cytosol and mitochondria.

Thiosugar-functionalized gold(I)-NHC complexes as selective anticancer agents for potential targeted therapy

Frontiers in Chemistry | DOI | Paper |

Background

This study reports four novel gold(I)-NHC complexes, two conjugated to a thiosugar moiety, designed as selective anticancer agents against ovarian cancer. The complexes were characterized and assessed for human serum albumin binding, lipophilicity, cytotoxicity in A2780 sensitive/resistant and SKOV-3 cells, and healthy HSkMC cells, plus TrxR inhibition, confocal microscopy and FACS uptake. Thiosugar conjugation improved potency, selectivity and cellular uptake, while peptide bioconjugates mostly failed to improve activity except LHRH-like peptide conjugates, which showed slight gains.

Key Findings

Four Au(I)-NHC complexes (1a-b, 2a-b) were synthesized; 2a-b bear 3,4,5,6-tetra-O-acetyl-1-thio-β-D-glucopyranose and an anthracenyl fluorescent tag. Thiosugar conjugation markedly enhanced cytotoxicity in A2780/S, A2780/R and SKOV-3 ovarian cancer cells, with IC50 values around 4–6 µM for 2a-b, while retaining >100 µM IC50 in healthy HSkMC cells and improving selectivity indices (>18) beyond auranofin. Confocal microscopy and FACS showed increased cellular uptake for 2a-b versus 1a-b. All complexes inhibited thioredoxin reductase; 2a was most effective. ESI-MS revealed HSA adducts for all complexes, but fluorescence quenching indicated reversible HSA binding only for non-thiosugar complexes 1a-b. GLUT-1 inhibition suggested thiosugar-mediated uptake partly for 2b, not 2a. Six peptide bioconjugates were synthesized; RGD and mitochondria-penetrating peptide conjugates lost selectivity, whereas LHRH analogue conjugates 9a-b showed slight cytotoxicity/selectivity improvement. Overall, thiosugar-functionalized Au(I)-NHC complexes are promising selective anti-ovarian cancer agents.

Contribution

Creative Bioarray provided the A2780/S and A2780/R human ovarian cancer cell lines (cisplatin-sensitive and cisplatin-resistant; lots CSC-C9491J, CSC-C9492J). These authenticated cell lines enabled cytotoxicity, TrxR inhibition, confocal, FACS uptake, and GLUT-1 inhibition assays, supporting evaluation of anticancer potency, selectivity, platinum-resistance overcoming, and thiosugar-mediated targeting of the gold(I)-NHC complexes.

FACS results for the complexes 1a, 2a, 1b, 2b in the A2780/S cell line (left) and the A2780/R cell line (right).
Fig. 3. FACS results for the complexes 1a, 2a, 1b, 2b in the A2780/S cell line (left) and the A2780/R cell line (right).

Bioconjugation of the gold drug auranofin to human ferritin yields a potent cytotoxin

Journal of Drug Delivery Science and Technology | DOI | Paper |

Background

This study prepares and characterizes a well-defined bioconjugate (HuHf@AF) between the gold drug auranofin and human heavy-chain ferritin/apoferritin, with ~14 gold atoms per nanocage. Site-directed mutagenesis, ESI-MS, and ICP-OES show gold binds exclusively to Cys90 and Cys102. HuHf@AF is highly cytotoxic against A2780 ovarian cancer cells, overcomes cisplatin resistance, and induces NMR metabolomic changes similar to free auranofin. It also metalates the thioredoxin reductase selenopeptide. The ferritin nanocage stabilizes and controls gold delivery, suggesting a promising anticancer agent.

Key Findings

A stable, reproducible auranofin–human H-ferritin bioconjugate (HuHf@AF) was prepared without cage disassembly, containing ~13.8 ± 3.8 gold atoms per nanocage. ESI-MS and ICP-OES, combined with site-directed mutagenesis, demonstrated that gold binds exclusively at solvent-exposed Cys90 and Cys102; C130A did not affect binding, whereas C90A/C102A abolished it. HuHf@AF was stable in glutathione and HSA competition assays. It showed potent cytotoxicity against A2780 ovarian cancer cells (IC50 0.26 µM) and was ~3-fold more active than free auranofin. HuHf@AF also overcame cisplatin resistance in A2780cis cells more efficiently than free auranofin. NMR metabolomics revealed metabolic alterations nearly identical to free auranofin, with marked glutathione increase. ESI-MS documented gold transfer to the TrxR C-terminal dodecapeptide. 19F NMR and pH 4.5 studies indicated efficient cellular uptake and acid-facilitated gold release.

Contribution

Creative Bioarray supplied the A2780 human ovarian cancer and A2780 cisplatin-resistant (A2780cis) cell lines used as in vitro models. These authenticated cells enabled cytotoxicity testing, cisplatin-resistance evaluation, and NMR metabolomic profiling, supporting the conclusion that HuHf@AF is a potent anticancer bioconjugate.

In vitro cytotoxic characterization
Fig. 4. In vitro cytotoxic characterization

Zein-Sodium Caseinate-Diosmin Nanoparticles as A Promising Anti-Cancer Agent with Targeted Efficacy Against A2780 Cell Line

This research investigated the potential of zein-sodium caseinate-diosmin nanoparticles (ZCD-NPs) as an anti-cancer agent against the A2780 cell line. Dynamic light scattering (DLS) analysis showed that ZCD-NPs have an average size of 265.30 nm with a polydispersity index of 0.21, indicating good uniformity suitable for pharmaceutical applications. Cytotoxicity assays showed a dose-dependent effect of ZCD-NPs, with A2780 cells showing significant sensitivity compared to normal HDF cells, indicating selective targeting of cancer cells. Flow cytometry analysis confirmed that ZCD-NPs induced apoptosis and necrosis in A2780 cells, as evidenced by increased expression of apoptotic genes such as p53 and caspases 8 and 9. In addition, ZCD-NPs exhibited potent antioxidant activity, effectively scavenging free radicals. These results suggest that ZCD-NPs have promising properties for targeted cancer therapy and antioxidant applications, which warrant further exploration in clinical settings.

Flow cytometry results indicate that ZCD-NPs induce apoptosis in A2780 cells in a concentration-dependent manner, with significant increases in apoptotic rates at higher concentrations.

Fig. 5. Flow cytometry results indicate that ZCD-NPs induce apoptosis in A2780 cells in a concentration-dependent manner (Faezi, Mahmoud, et al., 2025).

AO/PI staining analyses show that ZCD-NPs induce significant cytotoxic effects in A2780 cells, as evidenced by decreased green and increased red. DAPI staining further confirms a dose-dependent increase in nuclear condensation and fragmentation, characteristic of apoptosis.

Fig. 6. Fluorescence graph of A2780 cells stained with AO/PI and DAPI (Faezi, Mahmoud, et al., 2025).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products